ywvutsrpo Meeting Report: Strategic Workshops on Cancer Nanotechnology Larry A. Nagahara, 1 Jerry S.H. Lee, 1 Linda K. Molnar, 2 Nicholas J. Panaro, 3 Joseph Alper, 4 Piotr Grodzinski, 1 Anna D. Barker 5 1 Office of Technology and Industrial Relations, National Cancer Institute, Bethesda, Maryland 2 Science Applications International Corporation (SAIC), McLain, Virginia 3 Nanotechnology Characterization Laboratory, SAIC – Frederick, Inc., Frederick, Maryland 4 Parrotfish Consulting, Louisville, Colorado 5 Office of the Director, National Cancer Institute, Bethesda, Maryland Abstract: The National Cancer Institute (NCI) Alliance for Nanotechnology in Cancer is a comprehensive, systematized effort encompassing the academic and private sectors in multidisciplinary research and dedicated to the use of nanotechnology in cancer prevention, diagnosis, and therapy. The program is designed to move basic science discoveries into the development pipeline and eventually into clinical use. As the program approaches the midway point of its five-year funding, NCI is once again assessing the field of cancer nanotechnology to determine the current needs and gaps in this area of research. Toward that end, the NCI’s Office of Technology and Industry Relations (OTIR) held three strategic workshops on cancer nanotechnology covering the areas of in-vitro diagnostics and prevention, in-vivo diagnosis and imaging, therapy and post-treatment. To each of these meetings, NCI’s program staff invited a wide range of experts from academia, industry, the non-profit sector, and the Federal government, including those from the National Institutes of Health and the U.S. Food and Drug Administration. This meeting report is the summary and compilation of recommendations developed at these strategic workshops. 1 Submitted to Cancer Research